ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...
The drug, geranylgeranyltransferase inhibitor GGTI-2418 suppresses a new defective PTEN cancer pathway, researchers have discovered. A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt ...
PTEN, a tumor suppressor gene mutated in about 20% of prostate cancers, relies on another gene, ARID4B, to function. PTEN, a tumor suppressor gene mutated in approximately 20% of primary prostate ...
A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center's Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology ...
A means of determining whether the loss of the tumor suppressor gene PTEN predicts lethal outcomes in patients has been determined by a team from the Dana-Farber Cancer Institute. Using quantitative ...
ctDNA offers a minimally invasive alternative for detecting PIK3CA, AKT1, and PTEN alterations in hormone receptor-positive breast cancer when tissue is unavailable. The CAPItello-291 trial showed ...
In recent years, high-throughput technologies have provided unprecedented opportunities for analyzing cancer samples at multiple molecular levels. Each type of multi-omics dataset contributes to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback